Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists

Patent metadata

Field	Value
Publication number	US-2022249443-A1
Application number	US-202217718760-A
Country	US
Kind code	A1
Filing date	Apr 12, 2022
Priority date	Jun 21, 2016
Publication date	Aug 11, 2022
Grant date	—

Abstract

The present invention provides compounds of Formula (I):or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

First claim

What is claimed is:

1 . A compound of Formula (X):

wherein
R 20 is independently C 1-6 alkyl or H;
R 21 is independently C 1-6 alkyl or H; and
X 5 and X 6 are independently CH or N.

Assignees

• Bristol Myers Squibb Co

Inventors

• Cheng Peter Tai Wah
• Kaltenbach Iii Robert F
• Li Jun
• Shi Jun
• Shi Yan
• Tao Shiwei
• Zhang Hao
• Dhanusu Suresh
• Selvakumar Kumaravel
• Reddigunta Ramesh Babu
• Walker Steven J
• Kennedy Lawrence J
• Corte James R
• Fang Tianan
• Jusuf Sutjano

Classifications

• C07D249/06

  with aryl radicals directly attached to ring atoms · CPC title

• A61K31/4439 Primary

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title